Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $18.96 and traded as high as $20.02. Theravance Biopharma shares last traded at $19.82, with a volume of 263,756 shares traded.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Oppenheimer assumed coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price for the company. BTIG Research upped their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, November 26th. HC Wainwright lifted their target price on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $27.80.

Theravance Biopharma Stock Performance

The stock’s 50-day moving average is $18.96 and its two-hundred day moving average is $15.53. The stock has a market cap of $1.00 billion, a PE ratio of 34.77 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. Analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the transaction, the senior vice president owned 277,695 shares in the company, valued at $5,206,781.25. The trade was a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in TBPH. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. Creative Planning lifted its position in shares of Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 842 shares during the last quarter. State of Wyoming boosted its holdings in shares of Theravance Biopharma by 5.7% in the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,020 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.